ArticleOncotarget2017
Local application of bacteria improves safety of Salmonella -mediated tumor therapy and retains advantages of systemic infection.
Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Programmable Bacteria with Dynamic Virulence Modulation System for Precision Antitumor Immunity.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Hacking the Immune Response to Solid Tumors: Harnessing the Anti-Cancer Capacities of Oncolytic Bacteria.Pharmaceutics · 2023Review
- FimH and Type 1 Pili Mediated Tumor Cell Cytotoxicity by UropathogenicPathogens (Basel, Switzerland) · 2023Article
- Review
- Recent Advances in Bacteria-Based Cancer Treatment.Cancers · 2022Review
- A programmable encapsulation system improves delivery of therapeutic bacteria in mice.Nature biotechnology · 2022Article
- Ultrasound-controllable engineered bacteria for cancer immunotherapy.Nature communications · 2022Article
- Integration ofCancers · 2021Review
- Optimized AttenuatedFrontiers in microbiology · 2021Article
- Nanoerythrosome-functionalized biohybrid microswimmers.APL bioengineering · 2020Article
- Bacteria-cancer interactions: bacteria-based cancer therapy.Experimental & molecular medicine · 2019Review
- The motility regulator flhDC drives intracellular accumulation and tumor colonization of Salmonella.Journal for immunotherapy of cancer · 2019Article
- Strategies for developing and optimizing cancer vaccines.F1000Research · 2019Review
- Bacteria in Cancer Therapeutics: A Framework for Effective Therapeutic Bacterial Screening and Identification.Journal of Cancer · 2019Review
- Endostatin gene therapy delivered by attenuated Salmonella typhimurium in murine tumor models.Cancer gene therapy · 2018Article
- Tumor-targetingHeliyon · 2018Article
- Attenuated Bacteria as Immunotherapeutic Tools for Cancer Treatment.Frontiers in oncology · 2018Article
- Tumour-targeting bacteria-based cancer therapies for increased specificity and improved outcome.Microbial biotechnology · 2017Review
- EngineeredOncoimmunologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer is a devastating disease and a large socio-economic burden. Novel therapeutic solutions are on the rise, although a cure remains elusive. Application of microorganisms represents an ancient therapeutic strategy, lately revoked and refined via simultaneous attenuation and amelioration of pathogenic properties. Salmonella Typhimurium has prevailed in preclinical development. Yet, using virulent strains for systemic treatment might cause severe side effects. In the present study, we highlight a modified strain based on Salmonella Typhimurium UK-1 expressing hexa-acylated Lipid A. We corroborate improved anti-tumor properties of this strain and investigate to which extent an intra-tumoral (i.t.) route of infection could help improve safety and retain advantages of systemic intravenous (i.v.) application. Our results show that i.t. infection exhibits therapeutic efficacy against CT26 and F1.A11 tumors similar to a systemic route of inoculation. Moreover, i.t. application allows extensive dose titration without compromising tumor colonization. Adverse colonization of healthy organs was generally reduced via i.t. infection and accompanied by less body weight loss of the murine host. Despite local application, adjuvanticity remained, and a CT26-specific CD8+ T cell response was effectively stimulated. Most interestingly, also secondary tumors could be targeted with this strategy, thereby extending the unique tumor targeting ability of Salmonella. The i.t. route of inoculation may reap the benefits of systemic infection and aid in safety assurance while directing potency of an oncolytic vector to where it is most needed, namely the primary tumor.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.